Oxolinic acid: Difference between revisions
Appearance
Content deleted Content added
No edit summary |
Gareth CHEBI (talk | contribs) m ChEBI id added to Drugbox identifiers |
||
Line 41: | Line 41: | ||
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
||
| ChEMBL = 416755 |
| ChEMBL = 416755 |
||
| ChEBI_Ref = {{ebicite|correct|EBI}} |
|||
| ChEBI = 138856 |
|||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = 4467 |
| ChemSpiderID = 4467 |
Revision as of 14:11, 4 September 2014
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.035.213 |
Chemical and physical data | |
Formula | C13H11NO5 |
Molar mass | 261.23 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Oxolinic acid is a quinolone antibiotic developed in Japan in the 1970s.[1][2] Dosages 12–20 mg/kg orally administered for five to ten days. The antibiotic works by inhibiting the enzyme DNA gyrase. It also acts as a dopamine reuptake inhibitor and has stimulant effects in mice.[3]
See also
References
- ^ JP Patent 49138244
- ^ Gleckman R, Alvarez S, Joubert DW, Matthews SJ (August 1979). "Drug therapy reviews: oxolinic acid". American Journal of Hospital Pharmacy. 36 (8): 1077–9. PMID 384788.
{{cite journal}}
: CS1 maint: multiple names: authors list (link) - ^ Garcia de Mateos-Verchere J, Vaugeois JM, Naudin B, Costentin J (December 1998). "Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 8 (4): 255–9. doi:10.1016/S0924-977X(97)00083-7. PMID 9928913.
{{cite journal}}
: CS1 maint: multiple names: authors list (link)